2008 (23 Publikationen)

  • Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008; 34: 70-75 [IF 2.508]
  • Tatar O, Shinoda K, Kaiserling E, Pertile G, Eckardt C, Mohr A, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Early effects of triamcinolone acetonide on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Arch Ophthalmol 2008; 126: 193-199 [IF 3.242]
  • Yoeruek E, Spitzer MS, Tatar O, Biedermann T, Grisanti S, Lüke M, Bartz-Schmidt KU, Szurman P. Toxic effects of recombinant tissue plasminogen activator on human corneal endothelial cells. Invest Ophthalmol Vis Sci 2008; 49: 1392-1397 [IF 3.528]
  • Jaissle GB, Ulmer A, Henke-Fahle S, Fierlbeck G, Bartz-Schmidt KU, Szurman P. Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 2008; 144: 525-527 [IF 3.402]
  • Yoeruek E, Szurman P, Tatar O, Weckerle P, Wilhelm H. Anterior ischemic optic neuropathy due to giant cell arteritis with normal inflammatory markers. Graefes Arch Clin Exp Ophthalmol 2008; 246: 913-915 [IF 1.770]
  • Lüke M, Januschowski K, Beutel J, Lüke C, Grisanti S, Peters S, Kirchhof B, Bartz-Schmidt KU, Szurman P. The electrophysiological effects of Brilliant Blue G in the model of the isolated perfused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 2008; 246: 817-822 [IF 1.770]
  • Feudner EM, Gelisken F, Szurman P. Asymmetrisch ausgeprägte kristalline retinale Ablagerungen. Ophthalmologe 2008; 105: 384-388 [IF 1.133]
  • Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P. Tübingen Bevacizumab Study Group: Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol Scand 2008; 86: 322-387 [IF 2.138]
  • Bartz-Schmidt KU, Szurman P, Wong D, Kirchhof B. Neue Entwicklungen in der chirurgischen Therapie der rhegmatogenen Ablatio retinae. Ophthalmologe 2008; 105:27-36 [IF 1.133]
  • Ziemssen F, Zhu Q, Peters S, Grisanti S, El Wardani M, Szurman P, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group, Ziemssen T. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2008; 28: 101-109 []
  • Yoeruek E, Deuter CM, Szurman P, Tatar O, Zierhut M. Varicella-Zoster-Virus-assoziierte Skleromalazie. Ophthalmologe 2008; 105: 480-484 [IF 1.133]
  • Spitzer MS, Szurman P, Bartz-Schmidt KU. Correspondence: Intravitreal bevacizumab in postoperative pseudophakic cystoid macular edema: Does it really work? J Cataract Refract Surg 2008; 34: 880-881 [IF 2.508]
  • Szurman P. August consultation 4. J Cataract Refract Surg 2008; 34: 1234 [IF 2.508]
  • Jaissle GB, Bartz-Schmidt KU, Szurman P. Opticus-Atrophie nach epiretinalen Traimcinolon-Ablagerungen nach ILM-Peeling. Ophthalmologe 2008; 205: 575-577 [IF 1.133]
  • Tatar O, Yoeruek E, Szurman P, Bartz-Schmidt KU; Tübingen Bevacizumab Study Group, Adam A, Shinoda K, Eckardt C, Boeyden V, Claes C, Pertile G, Scharioth GB, Grisanti S. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126: 782-790 [IF 3.242]
  • Lüke M, Januschowski K, Beutel J, Warga M, Grisanti S, Peters S, Schneider T, Lüke C, Bartz-Schmidt KU, Szurman P. The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res 2008; 87: 22-29 [IF2.579]
  • Rohrbach JM, Szurman P, Bartz-Schmidt KU. 100 Jahre Universitäts-Augenklinik Tübingen. Klin Monatsbl Augenheilkd 2008; 225: 975-982 [IF 0.576]
  • Besch D, Sachs H, Szurman P, Gülicher D, Wilke R, Reinert S, Zrenner E, Bartz-Schmidt KU, Gekeler F. Extraocular surgery for implantation of an active subretinal viusal prosthesis with external connections: feasibility and outcome in seven patients; Br J Ophthalmol 2008; 92: 1361-1368 [IF 2.859]
  • Spitzer MS, Ziemssen F, Gelisken F, Bartz-Schmidt KU, Szurman P. Treatment of age-related macular degeneration: Focus on ranibizumab. Clin Ophthalmol 2008; 2: 1-14 [IF 1.031]
  • Spitzer MS, Yoeruek E, Kaczmarek RT, Sierra A, Aisenbrey S, Grisanti S, Bartz-Schmidt KU, Szurman P. Sodium hyaluronate gels as a drug release system for corticosteroids: Release kinetics and antiproliferative potential for glaucoma surgery. Acta Ophthalmol Scand 2008; 8: 842-848 [IF 2.138]
  • Spitzer MS, Batumba NH, Chirambo T, Kayange P, Szurman P. Ocular surface squamous neoplasia as first apparent manifestation of HIV infection in Malawi. Clin Exp Ophthalmol 2008; 36: 422-425 [IF 1.347]
  • Yoeruek E, Spitzer MS, Saygili O, Tatar O, Biedermann T, Yoeruek E, Bartz-Schmidt KU, Szurman P. Comparison of in vitro safety profiles of Vancomycin and cefuroxime on human corneal endothelial cells for intracameral use. J Cataract Refract Surg 2008; 34; 2139-2145 [IF 2.508]
  • Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008; 115; 1750-1755 [IF 5.296]

Kontakt

Callcenter:
06897 / 574-1121

Notfallambulanz (Pforte, außerhalb der Callcenter-Sprechzeiten):
06897 / 574-0

Privatambulanz (Chefarzt-Sekretariat):
06897 / 574-1119

Adresse:
Augenklinik Sulzbach, An der Klinik 10
66280 Sulzbach

Anfahrt

Online-Terminvergabe Patienten

Kontakt

KTQ Zertifikat

Wussten Sie schon?

Unser hohes Maß an Qualität wurde uns als erster Klinik im Saarland offiziell zertifiziert. Das KTQ-Siegel steht für Patientenorientierung, geprüfte Qualität und Sicherheit.